Loading...
TrendSpott

TrendSpott

TrendSpott
 
 
Geron
2.34
+0.43%
 
Recommendation
GERN Geron
  Login
 
 
Last Price
 
Change
 
2.34
 
+0.43%
 
 

 
Sentiment
 
  Login to display
 
 

2.66

2.42

2.27

1.66

 
 
1m
3m
6m
1y
 

Summary

  Login to display Geron (GERN) recommendation from the last 90 days from financial news and social media.
 

Rewards

Rewards

 Earnings are forecast to grow

 

Risk Analysis

Risk Analysis

 Insider selling during the past 3 months

 
 

Risk Level

 
TrendSpott
 

Geron (GERN) has Low Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 
Earnings ×
 

Earnings

2.00
 

TrendSpott

Below analyst estimate

 
 
Rating ×
 

Rating

NA
 
 
Momentum ×
 

Momentum

3.40
 
 
Activity ×
 

Activity

3.44
 

TrendSpott

Insider selling during the past 3 months

 
Future ×
 

Future

4.50
 

TrendSpott

Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is negative and it remained unchanged from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
66%
NA
70%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
66%
24%
Positive
Negative
19 out of 29
events present
7 out of 29
events present
 

 
Events Calendar
Click for more information
 
February
S
M
T
W
T
F
S
March
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Weak Earnings
1 Week Ago
2.65
+1.15%
 
Capital Raise
3 Month Ago
3.19
+32.92%
 
Top Headlines

geron gaap eps of -$0.10 beats by $0.03 revenue of $0.1m misses by $0.02m.

Thu Mar 16, 2023

Earnings

vancity announces new chief technology and information officer. territories of musqueam squamish and tsleil-waututh nations and vancouver british columbia march 06 2023 (globe newswire) -- vancity has announced that wendy murphy is the organization�

Mon Mar 6, 2023

Activity

2 top healthcare stocks to buy right now. geron corporation (nasdaq: gern) and idexx laboratories (nasdaq: idxx) are both poised to grow and make great long-term healthcare investments but for different reasons.

Mon Feb 13, 2023

Potential

geron (gern) stock sinks as market gains: what you should know. geron (gern) closed the most recent trading day at $3.34 moving -0.89% from the previous trading session. this change lagged the s&.p 500s 0.25% gain on the day. at the

Fri Jan 27, 2023

Momentum
Momentum

geron lines up commercial leadership for imetelstat launch.

Wed Jan 11, 2023

Activity

geron stock rises after pricing $198m securities offering.

Fri Jan 6, 2023

Momentum

geron (gern) up on imetelstat data on myelodysplastic syndromes. geron corporation gern announced positive top-line data from the phase iii imerge study evaluating its lead pipeline candidate imetelstat in lower risk myelodysplastic sy

Thu Jan 5, 2023

Activity

biotech stock roundup: gern surges on study data phat vera offer updates & more. the biotech sector was in focus with key pipeline and regulatory updates. among these geron corporation (gern) soared on positive study data.

Thu Jan 5, 2023

Activity
Momentum

why geron shares are trading lower by 13%. here are 20 stocks moving premarket. ) shares rose 110.4% to $1.62 in pre-market trading after the company said it has engaged lifesci capital as its advisor to explore strategic alternatives. ) rose 42% to $0

Thu Jan 5, 2023

Momentum

geron announces public stock offering of $175 mln shares slip 9%. (rttnews) - shares of geron corporation (gern) slipped nearly 9% in extended hours on wednesday after the late-stage clinical biopharmaceutical company announced its plan to offer

Wed Jan 4, 2023

Activity
Activity
Momentum

after-hours movers: geron lower on offering inter parfums gains on raised guidance.

Wed Jan 4, 2023

Momentum
Potential

geron dips 8.5% on $175m public offering.

Wed Jan 4, 2023

Activity

geron stock surges after encouraging data from rare blood cancer trial. ) announcedfrom its imerge phase 3 trial of imetel

Wed Jan 4, 2023

Activity
Momentum

geron imetelstat trial in lower risk mds meets primary efficacy goal. stock climbs in pre-market. (rttnews) - geron corp. (gern) a late-stage clinical biopharmaceutical company announced wednesday positive top-line results from its imerge phase

Wed Jan 4, 2023

Activity
Activity
Momentum

geron corps blood cancer drug succeeds in late-stage study. geron corp said on wednesday its experimental blood cancer drug helped more patients achieve independence from blood transfusions when compared with a placebo in a late-stage trial.

Wed Jan 4, 2023

Activity

 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss
 

Receive our daily GERN alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
TrendSpott

TrendSpott

Get the pulse of the market

 
TrendSpott

TrendSpott

GERN Geron

Last Price
2.34
Change
+0.43%
Recommendation
  Login to display
 

Summary

  Login to display Geron (GERN) recommendation from the last 90 days from financial news and social media.

 
 
2.66
2.42
2.27
1.66
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Rewards

Rewards

 Earnings are forecast to grow

Risk Analysis

Risk Analysis

 Insider selling during the past 3 months

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
NA
70%
100%
On Track
On Track
On Track
 
66%
24%
Positive
Negative
19 out of 29
events present
7 out of 29
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 
Earnings ×
 

Earnings

2.00
 

TrendSpott

Below analyst estimate

 
 
Rating ×
 

Rating

NA
 
 
Momentum ×
 

Momentum

3.40
 
 
Activity ×
 

Activity

3.44
 

TrendSpott

Insider selling during the past 3 months

 
Future ×
 

Future

4.50
 

TrendSpott

Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is negative and it remained unchanged from the past 3 months

 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Events Calendar
Hover for information
 
February
 
S
M
T
W
T
F
S
 
 
 
March
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Weak Earnings
1 Week Ago
2.65
+1.15%
 
Capital Raise
3 Month Ago
3.19
+32.92%
 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss

 

Receive our daily GERN Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines